ProCE Banner Activity

ASC4FIRST: Phase III Trial of Asciminib vs Investigator-Selected TKIs in Newly Diagnosed CML

Conference Coverage
Slideset

In the primary analysis of the phase III ASC4FIRST trial, asciminib demonstrated a statistically significant improvement in efficacy and a favorable safety profile compared with standard-of-care TKIs in newly diagnosed patients with chronic myeloid leukemia in chronic phase.

Released: June 03, 2024

Expiration: June 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi